Selank

—

evidence score

nootropic

Gray Market

TP-7tuftsin analogSelank nasal spray

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) analog of tuftsin developed by the Institute of Molecular Genetics in Moscow. It combines anxiolytic effects without sedation or dependence with immune modulation and mild cognitive enhancement. In Russian clinical trials it performed comparably to benzodiazepines for generalized anxiety disorder with superior cognitive profile (no impairment), no dependence, and without withdrawal. Pairs naturally with Semax (stimulating/activating) as Selank provides the anxiolytic/calming component. Used for generalized anxiety, PTSD, and as a cognitive enhancer under stress.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Research Sync

Not synced yet

Dosing

Typical

750 mcg

250 mcgRange3000 mcg

Frequency1-3x/day

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~2-3 minutes (plasma); effects persist hours via receptor changes

OnsetAnxiolytic effects within 15-30 minutes intranasally

DurationAcute effects 4-8 hours; anxiolytic benefits build over weeks

Routes

intranasal

subcutaneous_injection

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(40%)—

Quality(30%)—

Sample Size(10%)—

Consistency(10%)—

Replication(5%)—

Recency(5%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Selank is currently categorized as a nootropic compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Enkephalinase inhibition increases endogenous enkephalins; GABA-A modulation without direct binding; BDNF induction; IL-6/interferon modulation; serotonin normalization

Practical Context

Strongest current signals

No indexed study summaries yet.